- Home
- BLZE vs RIGL Comparison
BLZE vs RIGL Comparison
Compare BLZE & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLZE | RIGL |
|---|---|---|
| Founded | 2007 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.6M | 537.6M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | BLZE | RIGL |
|---|---|---|
| Price | $4.80 | $44.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $9.50 | ★ $43.20 |
| AVG Volume (30 Days) | ★ 816.6K | 529.1K |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2698.26 |
| EPS | N/A | ★ 6.20 |
| Revenue | $141,859,000.00 | ★ $282,076,000.00 |
| Revenue This Year | $16.43 | $65.53 |
| Revenue Next Year | $11.20 | $0.22 |
| P/E Ratio | ★ N/A | $7.09 |
| Revenue Growth | 15.73 | ★ 79.13 |
| 52 Week Low | $3.94 | $14.63 |
| 52 Week High | $10.86 | $52.24 |
Technical Indicators
Market Signals| Indicator | BLZE | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 39.94 | 55.88 |
| Support Level | $4.76 | $40.52 |
| Resistance Level | $4.98 | $43.58 |
| Average True Range (ATR) | 0.19 | 2.42 |
| MACD | 0.14 | -0.33 |
| Stochastic Oscillator | 56.72 | 48.65 |
Price Performance
Historical ComparisonAbout BLZE Backblaze Inc.
Backblaze Inc provides cloud storage services. The company offers services such as Backblaze B2 Cloud Storage, which enables customers to store data, developers to build applications, and partners to expand their use cases. It is offered as a consumption-based Infrastructure-as-a-Service (IaaS) and serves use cases including backups, multi-cloud, application development, and ransomware protection and Backblaze Computer Backup automatically backs up data from laptops and desktops for businesses and individuals. Geographically, it derives a majority of revenue from the United States and the rest from the United Kingdom, Canada, and Other regions.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.